Evidence map›Paper›PMID 36172173›Full record

ArticleTherapeutic advances in medical oncology2022

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.

Maria-Pilar Barretina-Ginesta, Bradley J Monk, Sileny Han, Bhavana Pothuri, Annika Auranen, Dana M Chase, Domenica Lorusso, Charles Anderson, Sophie Abadie-Lacourtoisie, Noelle Cloven and 10 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02655016 (A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02655016 phase3active not recruitingnot on this map

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

TypeinterventionalSponsorTesaro, Inc.Ran2016 to 2026Enrolled733ConditionsOvarian NeoplasmsArmsNiraparib, Placebo
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 7 countries.

Maria-Pilar Barretina-GinestaGEICO and Medical Oncology Department, Institut Català d'Oncologia, Sant Ponç, Avinguda de França, Girona 17007, SpainGirona Biomedical Research Institute, Girona University, Girona, Spain.ORCID https://orcid.org/0000-0003-0074-6614
Bradley J MonkGOG Foundation and Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ, USA.
Sileny HanBGOG and Department of Gynaecology and Obstetrics,University Hospitals Leuven, Leuven, Belgium.
Bhavana PothuriGOG Foundation and Department of Obstetrics/Gynecology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Annika AuranenNSGO and Department of Obstetrics and Gynecology and Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.
Dana M ChaseGOG Foundation and Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ, USA.
Domenica LorussoMITO and Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Charles AndersonGOG and Willamette Valley Cancer Institute, Eugene, OR, USA.
Sophie Abadie-LacourtoisieGINECO and Oncologie Médicale Gynécologique, Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France.
Noelle ClovenGOG and Division of Gynecologic Oncology, Texas Oncology (US Oncology Network), Fort Worth, TX, USA.
Elena I BraicuAGO and Department for Gynaecology, Campus Virchow Clinic, Charité - Universitätsmedizin Berlin, Berlin, GermanyDepartment of Obstetrics and Gynecology, Stanford University, Palo Alto, CA, USA.
Amnon AmitISGO and Division of Obstetrics and Gynecology, Rambam Medical Centre, Haifa, Israel.
Andrés RedondoGEICO and Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Ruchit ShahOpen Health Evidence and Access, Bethesda, MD, USAHealth Economics and Outcomes Research, Daiichi Sankyo, Basking Ridge, NJ, USA.
Nehemiah KebedeOpen Health Evidence and Access, Bethesda, MD, USAReal World Evidence Science, Oncology Business Unit, AstraZeneca, Gaithersburg, MD, USA.
Carol HawkesGSK, Brentford, UK.
Divya GuptaGSK, Waltham, MA, USA.
Tatia WoodwardGSK, Philadelphia, PA, USAGlobal Value and Evidence Strategy, Pfizer, Baltimore, MD, USA.
David M O'MalleyGOG and Division of Gynecologic Oncology, Ohio State University COM - James CCC, Columbus, OH, USA.
Antonio González-MartínGEICO and Medical Oncology Department, Clínica Universidad de Navarra, Madrid, SpainCIMA-University of Navarra, Program in Solid Tumors, Pamplona, Spain.ORCID https://orcid.org/0000-0001-8376-9576
Creighton University · USAstraZeneca (United States) · USClinica Universidad de Navarra · ESDaiichi Sankyo (United States) · USFondazione IRCCS Istituto Nazionale dei Tumori · ITGynecologic Oncology Group · USHospital Universitario La Paz · ESInstitut Català d'Oncologia · ESInstitut de Cancérologie de l'Ouest · FRKU Leuven · BEPfizer (United States) · USRambam Health Care Campus · ILStanford University · USTampere University Hospital · FITexas Oncology · USWillamette Valley Cancer Institute and Research Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The PRIMA phase 3 trial showed niraparib significantly prolongs median progression-free survival (PFS) Methods: Patients were randomized 2:1 to receive once-daily maintenance niraparib ( Results: The restricted mean QA-PFS was significantly longer with niraparib Conclusions: In patients with advanced OC, first-line niraparib maintenance was associated with significant gains in QA-PFS and Q-TWiST Trial registration: ClinicalTrials.gov: NCT02655016; trial registration date: January 13, 2016. Plain language summary:

Indexed as

maintenance therapyniraparibovarian cancerquality of life

Identifiers

PMID36172173
PMCPMC9511290
OpenAlexW4296640366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.